Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib Plus Hydroxychloroquine in COVID-19 Pneumonia
NCT04390061Phase 2Unknown
- Sponsor
- Università Politecnica delle Marche
- Start
- Jun 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of tofacitinib in COVID-19 pneumonia (2 arms), sponsored by Università Politecnica delle Marche. Primary endpoint: Prevention of severe Respiratory Failure requiring mechanical ventilation at 14 days. Status: unknown.
02
Drugs
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04390061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04390061.